Global IPO markets made steady gains in 2024, with IPO proceeds increasing compared to the previous year as the high interest ...

Cocoa extract supplementation among older adults had no effect overall on the occurrence of age-related macular degeneration ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Haleon launched a share buyback programme of up to £330m on Friday, representing the remaining portion of the £500m allocated ...

In early corporate news, SSE names Chief Commercial Officer Martin Pibworth as its new chief executive designate, while WH Smith agrees the sale of its UK High Street business. Here is what you need ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Kotak Alternate Asset Managers have announced an investment of ₹1,050 crore in Tirupati Medicare Ltd, a contract development ...

Haleon has named Nathalie Gerschtein as president North America, following Lisa Paley’s announcement to step down from her ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US ...

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

Pfizer has officially kissed goodbye to its consumer health venture by selling its final 7.3% stake in Haleon for a tidy $3.3 ...